| May 8th - Day One |
| Session 1 – Chairman’s Opening Address |
| A briefing of our industry today – are the needs of European value assessors realised in a
timely way and addressed appropriately? What changes are on the horizon and how
can we prepare. |
| Real World Data - Rick Lones, Executive Medical Director – BMS: |
- Eradicate the uncertainty of evidence in Clinical and Market Access conditions.
- Bridge the gap between Clinical Studies and real world settings.
|
Rick Lones, Executive Medical
Director and Chair of ABPI task force
on Real World Data, Bristol Myers Squibb |
| The impact of CER on the pharma industry and drug development |
- How are US payers leveraging comparative data to drive decisions – examples from Medco,
UnitedHealthcare, and WellPoint
|
Amy Rudolph, Head of Early Products
US Health Economics and Outcomes
Research, Novartis |
| European HTA address from Finn Borlum Kristensen at EUnetHTA |
- European perspective on HTA, what we are doing now and a description of the model we are moving towards. EUnetHTA presentation.
|
Professor Finn Børlum Kristensen,
Chairman of the EUnetHTA Executive
Committee, Danish National Board of
Health |
| Overview - dffi erent HTA approaches for pricing and reimbursement in diff erent EU
member states. |
- Translate results from Clinical Trials into fast Market Access, thorough HTA, Premium Pricing and
solid Reimbursement agreements.
- The future of reimbursement on Biosimilars – Vaccines - Personalized medicine and new
strategies for cost containment / tenders.
|
Dr. Ste ffen Thirstrup, VP, Danish
Medicines Agency |
| Case study: Launching and selling a pharmaceutical compound with the payer in mind. |
- Taking the needs and requests of payers across the world into account when developing a product
- Preparing and executing a communication strategy or payers
- Successfully developing a consistent payer and pricing strategy
|
Stefan Walzer, General Manager, AiM
Assessment in Medicine |
| Making sure external stakeholders understand and support your value proposition: |
- Get clinical and commercial teams to work together towards joint goals.
- Assess and coordinate your interaction with all external stakeholders.
- Deliver a relevant, aligned and impactful value messaging, by understanding stakeholder
perspectives and presenting the right messages in the right way.
|
Andrew Butcher, Partner, Atkinson Cowan |
| Ulf Staginnus leads a panel of Europe experts to discuss:
How can pharma prove payer value in drug development? |
- Bridge the gap between Clinical Studies and the real world setting.
- Integrate Market Access into clinical development.
- How payers can come in to advise Phase II studies – what components and data can you test to
prove examples.
- How can the medical value of drug discover and experimentation be enhanced not threatened by
payer and commercial trial endpoints. Find a balance that benefits patients.
|
Ulf Staginnus, Access Lead, Amgen
Dr. Ste en Thirstrup, VP, Danish
Medicines Agency
Flemming Sonne, CEO, Amgros
Andrew Butcher, Partner, Atkinson Cowan |
| "There is no clinical decision without commercial impact, no commercial decision that
does not have clinical consequence" Mike Rea shares: |
- His secrets to joining up clinical and non-clinical value evidence.
|
Mike Rea, CEO, IDEA pharma |
| Being the gatekeeper – How Amgros juggles its two big considerations: |
- The luxury of total budgetary control.
- The responsibility of making drugs available to the masses.
|
Flemming Sonne, CEO, Amgros |
| Relative Value Index 7 steps to value at Sanofi: |
- Payer engagement in clinical development through to Patient Access.
- Hear how Sanofi work to clinical and non-clinical proof of value.
|
Tehseen Salimi, MD MHA, VP Global
Evidence & Value Development, Sanofi |
| Hervé Drevot leads a panel of European experts to discuss: |
- How pharma and other stakeholders could work more eectively in generating data in the real life to
demonstrate attractive cost/benefit ratio?
- Patient Groups and Pharma – how can the industry brush to its negative image and enable patient
groups to share real insight that will help develop cures.
|
Philippe Fonjallaz, Merck Serono
Alex Stojanovic, Grunenthal
Susan Knox, European Breast Cancer
Coalition
Dr Dennis Lacombe, EORTC |
 |
 |
 |
Omar Ali, NHS & ERG COST
MODELING for NICE
Susan Knox, Executive Director
- European
Breast Cancer Coalition |
Herve Drevot, VP - CWHCP
Bruno Falissard , HAS
Marc Bardou, Commission de
Transparence at HAS
Dr Denis Lacombe, Director EORTC |
Mathias Flume, Kassenarztliche
Vereinigung Westfalen, Lippe
Detlev Parow, DAK-Gesundheit
|
| |
|
|
 |
 |
 |
Andres Navarro Ruiz, Hospital GU
|
Dr. Kjartan Christensen, Expert
Danish Market
Flemming Sonne, CEO, Amgros
Dr. Steff en Thirstrup, VP Danish
Medicines, Agency |
Mario Sano, Director of Pharmacy & Regional Drugs, Committee Rome |
